P ercutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) is associated with higher periprocedural complications compared with native vessel PCI because of distal embolization of atheroma from degenerative graft lesions leading to no-reflow phenomenon and periprocedural myocardial infarction (MI).
searches were performed, and related articles were reviewed. Reference lists of all related retrieved studies were also reviewed to complete our search. Two independent investigators performed the data collection from included studies (S.B. and T.K.P.). Data collection was then matched and reviewed by a third investigator (H.B.P.) for accuracy. All inconsistencies were resolved by discussion among all 3 investigators. The inter-rater agreement was 90%, and disagreements were resolved by consensus.
The main objective of this study was to compare all-cause mortality and MACE in patients who underwent SVG intervention using EPD versus without EPD. To be selected for analysis, a study had to meet all inclusion criteria: (1) study compares outcomes of SVG intervention using EPD versus without EPD and (2) study reports at least one of the following outcomes: all-cause mortality, MACE, periprocedural MI, late MI, and TVR. Studies that did not meet any of the above criteria were excluded.
After identifying all relevant articles, we extracted data from each study including authors, year of publication, study design, sample size, follow-up duration, and baseline clinical characteristics of patient population (Table 1) . End points extracted were all-cause mortality, MACE, periprocedural MI, TVR, and late MI up to 3 years after the procedure. Periprocedural MI was defined as an elevated creatine kinase (CK-MB) fraction >2 to 3 times the upper limit of normal within 24 hours of index procedure or during index hospitalization. Late or subsequent MI was defined as CK-MB elevation >3 times the upper limit of normal beyond index hospitalization up to 3 years of follow-up in any subsequent clinically driven measurements as available. When multiple follow-ups were available, we used the longest follow-up data.
Newcastle-Ottawa quality assessment scale was used to evaluate quality of the included studies (http://www.ohri.ca/programs/ clinical_epidemiology/oxford.htm). Briefly, studies were quoted by prespecified variables on patients' selection (representativeness and selection of patients and ascertainment of exposure), comparability of cohorts, and assessment of outcomes (recording and adequacy of follow-up). Score for each item was added, and a cumulative study quality score (maximal score, 9) was calculated. Two independent reviewers (H.B.P. and T.K.P.) performed the Newcastle-Ottawa Scale grading, and all discrepancies were resolved with consensus.
RevMan 5.3 statistical software was used to calculate odds ratios (OR) across all studies with corresponding 95% confidence interval (CI) for each end point (The Cochrane Collaboration, Copenhagen, Denmark). Heterogeneity of the studies was assessed for each end point. Heterogeneity was defined as I 2 >50% and χ 2 P value <0.01 as shown in Table 2 . All primary analyses were performed by random-effect model, and results were shown. Further analyses were performed by fixed-effect model for comparison of the results between the 2 models as shown in Table 3 . Sensitivity analysis was performed excluding studies and separately according to the types of the study. Publication bias was assessed using funnel plot and Egger test. A P value of <0.05 was considered to be statistically significant.
Results
Eight studies met the inclusion criteria and were included for the analysis. [4] [5] [6] [7] [8] [9] [10] [11] Literature search and the selection process are shown in Figure 1 . Studies overview, baseline patient characteristics, Newcastle-Ottawa quality assessment score, and outcomes are included in Table 1 . All studies received a score of >7 consistent with good quality. Publication bias and heterogeneity for each outcome are demonstrated in Table 2 • National Cardiovascular Data Registry CathPCI Registry study published in 2015 revealed no benefits in routine use of EPD during saphenous vein graft intervention and associated with a slightly higher incidence of periprocedural complications.
WHAT THE STUDY ADDS
• This study suggests that routine use of EPD during saphenous vein graft intervention is not associated with a reduction in all-cause mortality, major adverse cardiovascular events, myocardial infarction, or target vessel revascularization.
• Contrary to the expected benefit of the use of EPD, it was associated with 1.5-fold higher periprocedural myocardial infarction.
• With lack of evidence from >1 randomized trials, the present study adds further evidence on lack of benefit in routine use of EPD, supporting the need for re-evaluation of current guideline recommendations on EPD use during saphenous vein graft intervention in the current era. Table 3 . Overall, the results are consistent between the 2 models.
Discussion
Although RCTs have demonstrated efficacy and safety of EPDs in SVG intervention, the routine use of these devices has been controversial and continues to be a matter of debate. The results of this study including 52 893 patients revealed that allcause mortality and MACE rate were similar in EPD versus no-EPD use in SVG PCI. Similarly, there was no difference in periprocedural MI, late MI, and TVR. Surprisingly, when fixed-effect model was used, contrary to the expected benefit of the use of EPD, it was associated with 1.5-fold higher periprocedural MI (P<0.0001) compared with no-EPD. Because the main goal of EPD is to reduce no reflow and prevent periprocedural MI, the results of the current analysis question the necessity of a routine use of EPD in SVG intervention. Except for late MI and MACE, studies were homogenous for the outcomes of all-cause mortality, periprocedural MI, and TVR. 11 NCDR CathPCI Registry study 11 has the largest sample size compared with other studies, and this may skew the results of this study. Thus, sensitivity analysis was performed excluding NCDR CathPCI Registry study showing studies were homogenous for all outcomes. There was no significant difference in periprocedural MI, late MI, and TVR between EPD versus no-EPD groups. However, all-cause mortality and MACE differ significantly between the 2 groups favoring EPD use. These pooled estimates of the 7 studies were compared directly with the results of the CathPCI Registry. Periprocedural MI was higher in EPD group in CathPCI Registry, but the pooled estimate showed no difference in periprocedural MI between the 2 groups. The CathPCI Registry study showed similar risk of late MI and TVR between EPD and no-EPD groups, which is consistent with pooled estimates. With regard to outcomes of all-cause mortality and MACE, there was no difference by CathPCI data, whereas pooled analysis showed a difference favoring EPD use. Further sensitivity analysis performed including only observational studies showed no difference in all-cause mortality, MACE, late MI, and TVR between the 2 groups. When fixed-effect model was used, a significant difference was observed in late MI favoring no-EPD use. Additional analysis on observational studies was performed after excluding NCDR CathPCI Registry study, which revealed no statistically significant difference in outcomes. When only observational studies were used for analysis, studies were homogenous for all the outcomes either including or excluding NCDR CathPCI Registry study. Of note, an initial analysis of 8 studies showed that studies were homogenous for all-cause mortality, periprocedural MI, and TVR even inclusive of the NCDR CathPCI Registry study. Therefore, probably NCDR CathPCI Registry data are not the main factor for different results when excluding this study from initial analysis. However, unknown confounders could not be determined in this meta-analysis. The analysis was not performed only including RCTs because there were 2 RCTs, and 1 of them was underpowered. Subgroup analysis based on study quality was not performed because all the included studies were of good quality.
The In these 2 trials, the benefit of EPD use was limited to a reduction in periprocedural MI. However, regardless of EPD use, the periprocedural event rates remained ≈10% across the studies, indicating that EPD use was not always successful. 4, 9, 18, [20] [21] [22] It is also important to mention that none of these 3 randomized studies reported long-term follow-up data.
There were several studies published subsequently on the use of EPD in SVG intervention that have shown conflicting results.
5-10 Dixon et al 5 conducted a randomized multicenter trial (TRAP trial) that used the TRAP distal vascular filtration system showing no difference in MACE, all-cause mortality, MI, and TVR between TRAP and control group at 30 days. Because of slow enrollment, the study was terminated early as there was another approved distal protection device available at the same time. Thus, the study lacked power to detect a difference. Despite it being a randomized trial, lack of adequate power and absence of long-term follow-up data were major limitations of this study. A retrospective study of 202 SVG interventions demonstrated no statistically significant difference in MACE at 30 days (13.9% versus 9.6%; EPD versus no-EPD). 9 A prospective observational study including 534 patients who underwent SVG PCI showed similar in-hospital events including death, MACE, and MI. 7 Another retrospective study by Golwala et al 6 revealed that EPD use during SVG PCI did not improve the primary end point of periprocedural MI, but the secondary end point of MACE was significantly reduced at 1-year follow-up driven by reduced TVR because no difference in death and MI was noted. This lower TVR may be due to larger caliber vessels/stents because EPD is generally used in vessels between 3 and 5 mm, and larger stents decrease future revascularization rate. Moreover, a reduced TVR rate may be because of contemporary use of drug-eluting stents instead of bare metal stents rather than beneficial effect of EPD itself. Another prospective observational study showed no difference in death, MI, TVR, and MACE in-hospital, at 1-and 6-month follow-ups. 10 A propensity-matched analysis of British Columbia Cardiac Registry data including 1359 patients showed no difference in mortality at 1-and 2-year follow-ups. 7 TVR was lower at 1 year but similar at 2 years. 7 These data suggest that the short-term benefits observed in the SAFER trial may not have sustained at longer term follow-up not only for TVR but also for other outcomes because longer follow-up did not show any difference across studies including ours. Moreover, a large NCDR CathPCI Registry study showed no benefits in routine use of EPD during SVG intervention.
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Rather, this registry showed that use of EPD was associated with slightly higher incidence of no-reflow, vessel dissection, perforation, and periprocedural MI. These results raised questions about the safety and efficacy of EPDs in routine SVG intervention and a concern about the relevance of existing randomized data to contemporary clinical practice. Despite a Class I recommendation, we found the utilization of EPD in SVG intervention to be low (21.7%), which is consistent with previous literature, 7, 11, 23 with even a decreasing trend in EPD use over time. 7 There are several explanations for this lower rate of EPD use. The use of EPD increases the procedure time and complexity and cannot be used in all SVGs because of size, anatomic location, and lesion complexity. 4, 12 Mathew et al 24 have shown that approximately half of the SVG lesions were not suitable for EPD; 42% and 57% of SVG lesions failed to meet the inclusion criteria for filter wire and balloon occlusion, respectively. Even if EPD can be used, it may not completely seal the distal vessel and be unsuccessful in preventing distal embolization. Additionally, EPD use is associated with procedural complications including vessel perforation, dissection, and device entrapment. 4, 11 Simpler technique such as direct stenting, 25 undersizing stents with higher stent/lesion length ratio, and periprocedural vasodilator therapy 26 has been proven beneficial in preventing noreflow phenomenon that may limit the benefits of EPD use. Studies showed that without visible thrombus, prophylactic use of intragraft abciximab and vasodilators including verapamil, adenosine, or nicardipine combined with or without direct stenting is a safe and effective strategy to prevent distal microembolization and no-reflow phenomenon in SVG intervention. [25] [26] [27] Anecdotally, aspiration catheters and lowdose intragraft tPA (tissue-type plasminogen activator) has been used in SVG interventions by operators in selected cases with benefits to prevent or treat no-reflow where thrombus is visible.
The results of this meta-analysis showed no difference in clinical outcomes. Potential explanations are the currently available more potent pharmacotherapy, pretreatment with dual antiplatelet therapy, improved procedural techniques, and advent of contemporary interventional devices, which are less bulky and highly deliverable. Furthermore, devices for efficient vasodilator delivery to distal vessel have helped in managing no-reflow phenomenon in SVG PCI. Therefore, the routine use of EPD in SVG intervention may not be necessary and beneficial, but EPD utilization may still be useful in selected higher risk patients. EPD probably prevent macroembolization and may be beneficial in intervention of SVGs with heavy thrombus burden or large lipid-laden plaque with higher distal embolization risk.
With lack of evidence from >1 randomized trials, the present meta-analysis would add further evidence on lack of benefit of routine use of EPD supporting re-evaluation of the need for EPD in routine use during SVG intervention. It is difficult to make firm conclusions, given that the EPD patients were chosen by operators, and the unmeasured confounders make it difficult to be definitive. Future randomized controlled EPD trials are needed with the advent of new technologies and newer pharmacotherapies in current real-world practice. Meanwhile, guideline recommendation for routine use of EPD in SVG intervention may need to be revisited.
This meta-analysis has several limitations. Because this is not a patient-level meta-analysis, the effects of age, sex, race, and ethnic background on outcomes could not be assessed. Although there is a potential for publication bias as is true for all meta-analyses, this analysis shows that there is no publication bias for any outcome. Included studies did not provide data required for this study uniformly, and hence, for comparison of various outcomes, different set of studies were used. Power analysis was not performed in most of the studies, and many of these studies may have been underpowered. Importantly, there are only 2 RCTs comparing EPD versus no-EPD, 4, 5 and rest are registry data, 7,11 prospective, 8, 10 and retrospective 6, 9 observational studies with wide range of sample sizes. Except NCDR CathPCI Registry, other studies including 2 RCTs (Baim, n=801, and Dixon, n=358) have small sample size (n=150-1359), as such evidence from these studies are diverse and may not be strong. The individual studies have their own limitations that also reflect on this analysis, especially prospective and retrospective observational studies that are prone to selection bias. One RCT was underpowered to detect the difference in outcomes. 5 The end points for each outcome were not reported homogenously across studies, and follow-up time varied such as in-hospital, 30 days, 6 months, 1 year, 2 years, and 3 years. The definition of MACE was not universal; although death, MI, and TVR were common components of the MACE, 6, 8, 9 ,11 2 studies included coronary artery bypass surgery 4, 5 and 1 study included in-stent thrombosis and target lesion revascularization as part of MACE. MI was defined as CK-MB level >3 times upper limit of normal [4] [5] [6] 9 and >2 times upper limit of normal. The study by Iqbal et al 7 was excluded from the analysis for the outcomes of periprocedural and late MI as TIMI (Thrombolysis in Myocardial Infarction) 2 to 3 flow was used as a surrogate marker for MI. Individual study lacks data on angiographic subsets for the outcomes of the study for further analysis. Use of EPD in specific angiographic subset may gain more benefits compared with other subsets, and without angiographic subgroup analysis, it is hard to make definitive conclusion in this regard. Previous MI may be a potential confounder, and 2 RCTs excluded patients with recent or acute MI at baseline. Three observational studies included patients with history of MI and showed no difference in baseline characteristics between EPD and no-EPD groups. [7] [8] [9] Other 3 observational studies did not presented previous MI data in the baseline characteristics, but previous MI was included as a variable in the regression model for adjustment in the CathPCI Registry study. The strength of this meta-analysis is that there is no publication bias, and studies are homogenous for the outcomes when sensitivity analysis was performed. Additionally, quality assessment score demonstrated that all studies were of good quality. Furthermore, analyses were performed using both random-and fixed-effect models, and results were consistent across strata, strengthening the association of no difference in outcomes. 
